These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 16406864)

  • 1. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The case for secondary hormonal therapies in the chemotherapy age.
    Small EJ; Ryan CJ
    J Urol; 2006 Dec; 176(6 Pt 2):S66-71. PubMed ID: 17084172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary hormonal manipulations in the management of advanced prostate cancer.
    Chaudhary UB; Rashid MH; Onitilo AA; Bissada NK
    Can J Urol; 2005 Jun; 12(3):2666-76. PubMed ID: 16011813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hormone refractory prostate cancer: current standards and future prospects.
    Oh WK; Kantoff PW
    J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
    BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary hormonal therapy.
    Smith DC
    Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing prostate cancer: the role of hormone therapy.
    Ramirez ML; Keane TE; Evans CP
    Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment of advanced prostate cancer.
    Ismail M; Gomella LG
    Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer: the role of hormonal therapy.
    Salesi N; Carlini P; Ruggeri EM; Ferretti G; Bria E; Cognetti F
    J Exp Clin Cancer Res; 2005 Jun; 24(2):175-80. PubMed ID: 16110748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in hormonal therapy for advanced prostate cancer.
    Daskivich TJ; Oh WK
    Curr Opin Urol; 2006 May; 16(3):173-8. PubMed ID: 16679855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
    Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
    Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hormonal manipulations in prostate cancer.
    Ryan CJ
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):925-34. PubMed ID: 16861123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.